// App-Quantinova.ai

: Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Researchers

Presenter

  • Veronica Gonzalez-Calle

Principal Investigators

  • Beatriz Rey-Bua

  • Javier de la Rubia

  • Felipe de Arriba

  • Valentin Cabanas

  • Esther González Garcia

  • Enrique M. Ocio

  • Cristina Encinas

  • Alexia Suarez Cabrera

  • Joan Bargay

  • Joaquin Martinez Lopez

  • Marta Sonia Gonzalez

  • Jose Angel Hernandez-Rivas

  • Laura Rosinol

  • Miguel-Teodoro Hernandez

  • Bruno Paiva

  • Maria Teresa Cedena Romero

  • Noemi Puig

  • Juan-Jose Lahuerta

  • Joan Blade

  • Jesus San-Miguel

  • Maria-Victoria Mateos

Medical Centers

  • Hematology Department, University Hospital of Salamanca, Salamanca, Spain

  • Hematology Department, Hospital Universitari i Politècnic La Fe, Catholic University of Valencia, Valencia, Spain

  • Hospital Clínico Universitario Virgen de la Arrixaca. IMIB-Arrixaca. University of Murcia, Murcia, Spain

  • Hospital Universitario de Salamanca,Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain

  • Hospital De Octubre, Complutense University, CNIO, Madrid, Spain

  • Hematology, Hematology Department, Hospital Clinic i Provincial, IDIBAPS, Barcelona, Spain

  • Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, ESP

  • Hospital De Octubre, Madrid, Spain

  • Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, SANTIAGO DE COMPOSTELA, Spain

  • Hospital Universitario Marqués de Valdecilla (IDIVAL), Santander, Spain, Santander, Spain

  • Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain

  • Hematology Department, Hospital General Universitario Gregorio Marañón, MADRID, ESP

  • Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB//, Pamplona, Spain

  • Hospital Universitario de Cabueñes, Gijón, Spain

  • Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

  • Department of Hematology, Hospital Universitario Infanta Leonor, Universidad Complutense, Madrid, Spain

  • Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Spain

  • Departamento de Hematología, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain

  • Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain

  • Hematology and Hemotherapy Department, Clínica Universidad de Navarra, Pamplona, Spain

  • Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

  • Hospital Son Llatzer, Palma De Mallorca, Spain

  • Hospital Universitario de Octubre; Instituto de Investigación Sanitaria Hospital Universitario de Octubre i+,HO-CNIO Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • GSK2857916

  • Melphalan

Outcome

  • N/A

Study Design

  • Randomized

  • Efficacy

  • Safety

  • Open Label

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved